Bard Financial Services Inc. Has $974,000 Stake in Sanofi (NASDAQ:SNY)

Bard Financial Services Inc. trimmed its position in shares of Sanofi (NASDAQ:SNY) by 20.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,900 shares of the company’s stock after selling 4,450 shares during the quarter. Bard Financial Services Inc.’s holdings in Sanofi were worth $974,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Vestal Point Capital LP acquired a new stake in shares of Sanofi during the 4th quarter valued at about $14,919,000. Dynamic Advisor Solutions LLC raised its stake in shares of Sanofi by 39.2% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock valued at $2,780,000 after acquiring an additional 16,117 shares in the last quarter. Manning & Napier Advisors LLC bought a new position in shares of Sanofi in the 2nd quarter valued at approximately $13,725,000. Mount Yale Investment Advisors LLC raised its stake in shares of Sanofi by 44.3% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after acquiring an additional 12,806 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in shares of Sanofi by 18.9% in the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock valued at $9,216,000 after acquiring an additional 30,115 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on SNY shares. StockNews.com raised Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Argus lifted their price target on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

NASDAQ SNY traded down $0.07 during trading on Friday, hitting $55.47. The company’s stock had a trading volume of 3,077,855 shares, compared to its average volume of 1,583,234. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The firm has a 50 day moving average price of $55.52 and a 200 day moving average price of $51.09. The firm has a market cap of $140.76 billion, a P/E ratio of 27.87, a price-to-earnings-growth ratio of 1.58 and a beta of 0.60. Sanofi has a 52 week low of $42.63 and a 52 week high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.95 EPS. Equities research analysts forecast that Sanofi will post 4.26 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.